

The screenshot shows the metastatic trial search interface. At the top, there are filters for 'Filter by Location / Phase', 'Filter by Trial Type', and 'Filter by Mutations', along with a search bar. Below these are checkboxes for 'Trials added within the last 2 weeks' and 'Trials with no visits required'. A yellow banner encourages registration: 'Why register? Save your profile, save trials, and enter treatment history for more accurate matching.' with a 'LOGIN / REGISTER' link.

The first trial listing is titled '1 XL092 Targeted Therapy for Advanced HR+, HER2- Breast Cancer'. It includes a 'Show Scientific Title' button, a description of the study, a 'Purpose' section, and a 'Who is this for?' section. On the right, it lists the 'Nearest Location' (3 miles, Exelixis Clinical Site #66, San Francisco, CA), 'Visits' (1 visit every 3 weeks), 'ClinicalTrials.gov' link (NCT03845166), and 'Phase I'. A 'Full Trial Details' button is also present.

The second trial listing is titled '2 Registry to Study Advanced Breast Cancer and Treatment Response'. It also shows the 'Nearest Location' (3 miles).


At the bottom of the first trial listing, there are links to 'Save Trial', 'Share with a provider', 'Share with a patient', 'View Locations & Contact Info', and 'Print'.

While looking over your list of trials, here are some helpful tips for reviewing each listing.

- MTS summarizes the title and purpose of each trial.
- You can also click "Show Scientific Title" to see the official scientific title for this trial.
- The "Who is this for?" section summarizes the main requirements for participating in each trial, which are called eligibility criteria. The full set of criteria is also available by clicking the "View full eligibility criteria" link.
- On the right side, you can quickly see the nearest location to your zip code, the estimated number of visits required, a link to the official government listing on ClinicalTrials.gov, and the phase.

★ **Remember:** Help is always available.

To see the complete trial summary, click “Full Trial Details.”



therapy for advanced/metastatic disease. [View full eligibility criteria](#)

**What's involved?**  
You will be assigned to 1 of 2 groups:

**Group 1**

- XL092, by mouth

**Group 2**

- XL092, by mouth
- Atezolizumab (Tecentriq®), by IV, every 3 weeks

**What's being studied?**

- XL092 is an experimental targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.
- Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.
- This trial is also enrolling people with other types of cancer.

**How can I learn more?**

- View eligibility criteria and additional trial information: [ClinicalTrials.gov](#)
- Exelixis: [XL092 Drug Information Page](#)
- [Breastcancer.org: Atezolizumab \(Tecentriq®\)](#)

[Hide Details](#)

☆ [Save Trial](#)   [Share with a provider](#)   [Share with a patient](#)   [View Locations & Contact Info](#)   [Print](#)

- The “What’s involved” section is an overview of the treatment plan to get an idea of what would be involved if you were to enroll.
- The “What’s being studied” section is where you can find more information about the drugs and/or procedures in this trial.
- The “How can I learn more” section provides links to additional information to help you better understand the trial drugs or procedures.



**Remember:** Help is always available.